Objekt-Metadaten

Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis
Baygan, Arjang ;  Aronsson-Kurttila, Wictor ;  Moretti, Gianluca ;  Tibert, Babylonia ;  Dahllof, Goran ;  Klingspor, Lena ;  Gustafsson, Britt ;  Khoein, Bita ;  Moll, Guido ;  Hausmann, Charlotta ;  Svahn, Britt-Marie ;  Westgren, Magnus ;  Remberger, Mats ;  Sadeghi, Behnam ;  Ringden, Olle

HaupttitelSafety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis
AutorBaygan, Arjang
AutorAronsson-Kurttila, Wictor
AutorMoretti, Gianluca
AutorTibert, Babylonia
AutorDahllof, Goran
AutorKlingspor, Lena
AutorGustafsson, Britt
AutorKhoein, Bita
AutorMoll, Guido
AutorHausmann, Charlotta
AutorSvahn, Britt-Marie
AutorWestgren, Magnus
AutorRemberger, Mats
AutorSadeghi, Behnam
AutorRingden, Olle
Seitenzahl10 Seiten
Freie Schlagwörtergraft-versus-host disease; mesenchymal stromal cells; hematopoietic stem cell transplantation; hemorrhagic cystitis; decidual stromal cells
DDC610 Medizin und Gesundheit
616 Krankheiten
Auch erschienen inFrontiers in Immunology. - 8 (2017), 795
ZusammenfassungMesenchymal stromal cells (MSCs) are increasingly used in regenerate medicine. Placenta-derived decidual stromal cells (DSCs) are a novel therapy for acute graft-versus-host-disease (GVHD) and hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT). DSCs are more immunosuppressive than MSCs. We assessed adverse events and safety using DSCs among 44 treated patients and 40 controls. The median dose of infused cells was 1.5 (range 0.9–2.9) × 106 DSCs/kg. The patients were given 2 (1–5) doses, with a total of 82 infusions. Monitoring ended 3 months after the last DSC infusion. Three patients had transient reactions during DSC infusion. Laboratory values, hemorrhages, and transfusions were similar in the two groups. The frequency of leukemic relapse (2/2, DSC/controls) and invasive fungal infections (6/6) were the same in the two groups. Causes of death were those seen in HSCT patients: infections (5/3), respiratory failure (1/1), circulatory failure (3/1), thromboembolism (1/0), multiorgan failure (0/1), and GVHD and others (2/7). One-year survival for the DSC patients with GVHD was 67%, which was significantly better than achieved previously at our center. One-year survival was 90% in the DSC-treated HC group. DSC infusions appear safe. Randomized studies are required to prove efficacy.
Dokumente
PDF-Datei von FUDOCS_document_000000027467
Falls Ihr Browser eine Datei nicht öffnen kann, die Datei zuerst herunterladen und dann öffnen.
 
Fachbereich/EinrichtungMedizinische Fakultät Charité - Universitätsmedizin Berlin
Erscheinungsjahr2017
Dokumententyp/-SammlungenWissenschaftlicher Artikel
SpracheEnglisch
RechteCreative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Anmerkungen des AutorsDer Artikel wurde in einer Open-Access-Zeitschrift publiziert.
Erstellt am28.07.2017 - 09:26:47
Letzte Änderung28.07.2017 - 09:28:25
 
Statische URLhttp://edocs.fu-berlin.de/docs/receive/FUDOCS_document_000000027467
DOI10.3389/fimmu.2017.00795
ISSN1664-3224
Zugriffsstatistik
 

LOADING...